Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Novartis Halts Trial of Nilotinib in GIST

TOP - March/April 2011, VOL 4, NO 2 published on October 1, 2012

Novartis has discontinued a phase 3 trial assessing whether its TKI nilotinib (Tasigna) might be a more effective first-line therapy than imatinib (Gleevec) in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs). Nilotinib has shown better efficacy than imatinib in patients with newly diagnosed chronic myeloid leukemia and is approved for this indication. Investigators were disappointed that nilotinib did not similarly outperform imatinib in GIST.

Last modified: July 22, 2021